ODEVIXIBAT

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C37H48N4O8S2
Molecular Weight	740.929
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of ODEVIXIBAT

Structure Search

SMILES

CCCCC1(CCCC)CN(C2=CC=CC=C2)C3=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C4=CC=C(O)C=C4)C=C3S(=O)(=O)N1

InChI

InChIKey=XULSCZPZVQIMFM-IPZQJPLYSA-N

InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C37H48N4O8S2
Molecular Weight	740.929
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:35:34 UTC 2023` Edited by `admin` on `Sat Dec 16 17:35:34 UTC 2023`
Record UNII	2W150K0UUC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ODEVIXIBAT

Official Name

English

BUTANOIC ACID, 2-(((2R)-2-((2-((3,3-DIBUTYL-2,3,4,5-TETRAHYDRO-7-(METHYLTHIO)-1,1-DIOXIDO-5-PHENYL-1,2,5-BENZOTHIADIAZEPIN-8-YL)OXY)ACETYL)AMINO)-2-(4-HYDROXYPHENYL)ACETYL)AMINO)-, (2S)-

Systematic Name

English

AZD8294

Code

English

A-4250

Code

English

Odevixibat [WHO-DD]

Common Name

English

AZD-8294

Code

English

BUTANOIC ACID, 2-(((2R)-((((3,3-DIBUTYL-2,3,4,5-TETRAHYDRO-7-(METHYLTHIO)-1,1-DIOXIDO-5-PHENYL-1,2,5-BENZOTHIADIAZEPIN-8-YL)OXY)ACETYL)AMINO)(4-HYDROXYPHENYL)ACETYL)AMINO)-, (2S)-

Systematic Name

English

ODEVIXIBAT [USAN]

Common Name

English

ODEVIXIBAT [ORANGE BOOK]

Common Name

English

A4250

Code

English

AR-H064974

Code

English

odevixibat [INN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

658118

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

FDA ORPHAN DRUG

370812

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

FDA ORPHAN DRUG

371012

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

FDA ORPHAN DRUG

370912

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

EU-Orphan Drug

EU/3/18/2103

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

Code System Code Type Description

EPA CompTox

DTXSID601336860

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

RXCUI

2563966

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

NCI_THESAURUS

C166598

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

EVMPD

SUB193727

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

SMS_ID

100000178132

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

PUBCHEM

10153627

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

INN

10706

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

FDA UNII

2W150K0UUC

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

CAS

501692-44-0

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

DAILYMED

2W150K0UUC

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

USAN

GH-119

Created by admin on Sat Dec 16 17:35:34 UTC 2023 , Edited by admin on Sat Dec 16 17:35:34 UTC 2023

PRIMARY

Related Record Type Details


					Q76KP2H4XW

ODEVIXIBAT SESQUIHYDRATE

SOLVATE->ANHYDROUS


					Q76KP2H4XW

ODEVIXIBAT SESQUIHYDRATE

SALT/SOLVATE -> PARENT

Amount:


					6IUSRNBJ8Q

ILEAL SODIUM/BILE ACID COTRANSPORTER

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					2W150K0UUC

ACTIVE MOIETY

Comments:

Originator: Albireo; Class: Antipruritic; Mechanism of Action: Sodium-bile acid cotransporter-inhibitor; Orphan Drug Status: Yes for Primary biliary cirrhosis, Intrahepatic cholestasis, Alagille syndrome; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Phase II for Intrahepatic cholestasis, Primary biliary cirrhosis, Pruritus - Phase I for Alagille syndrome; Most Recent Events: 25 Jul 2016 Phase-II clinical trials in Intrahepatic cholestasis (PO) (Albireo pipeline, July 2016), 06 Nov 2015 Phase-II clinical trials in Pruritus (In adolescents, In children, In infants) in Germany (PO) (EudraCT2015-001157-32), 21 Aug 2015 Phase-II clinical trials in Pruritus (In children, In infants, In adolescents) in Denmark (PO) (EudraCT2015-001157-32)